Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $59.2 million.

  • TransMedics' Cost of Revenue rose 2364.97% to $59.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.9 million, marking a year-over-year increase of 3792.26%. This contributed to the annual value of $179.5 million for FY2024, which is 10502.57% up from last year.
  • TransMedics' Cost of Revenue amounted to $59.2 million in Q3 2025, which was up 2364.97% from $60.8 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Cost of Revenue ranged from a high of $60.8 million in Q2 2025 and a low of $1.6 million during Q3 2021
  • Its 5-year average for Cost of Revenue is $25.2 million, with a median of $15.7 million in 2023.
  • As far as peak fluctuations go, TransMedics' Cost of Revenue tumbled by 2221.14% in 2021, and later soared by 37388.85% in 2022.
  • Quarter analysis of 5 years shows TransMedics' Cost of Revenue stood at $2.7 million in 2021, then skyrocketed by 297.91% to $10.7 million in 2022, then skyrocketed by 211.56% to $33.2 million in 2023, then soared by 49.21% to $49.6 million in 2024, then increased by 19.43% to $59.2 million in 2025.
  • Its Cost of Revenue was $59.2 million in Q3 2025, compared to $60.8 million in Q2 2025 and $55.3 million in Q1 2025.